Yüklüyor......

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma

Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cell Oncol
Asıl Yazarlar: Smalley, Keiran SM, Fedorenko, Inna V
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2015
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4905349/
https://ncbi.nlm.nih.gov/pubmed/27308505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1008291
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!